May 10 -- Allergan is planning a buyback of as much as $10 billion of stock after completing the sale of its generics business to Teva Pharmaceuticals. Bloomberg's Drew Armstrong reports with comments from Charles Kantor, senior portfolio manager at Neuberger Berman, on "Bloomberg ‹GO›."
RECOMMENDED FOR YOU
